期刊文献+

TRAIL对糖尿病大鼠主动脉的保护作用

Protection of aorta from atherosclerosis in diabetic rats with TRAIL
原文传递
导出
摘要 4周龄雄性SD大鼠经高脂喂养8周后予小剂量链脲佐菌素腹腔注射以建立糖尿病模型,分为糖尿病组和瘤坏死因子相关的凋亡诱导配体(tumor necrosis factor-related apoptosis ligand,TRAIL)干预组,另选正常SD大鼠为对照组.TRAIL干预3个月.与糖尿病组相比,TRAIL干预组总胆固醇、甘油三酯、血糖、胰岛素显著降低,大鼠主动脉粥样斑块病变面积及光镜下内膜厚度减小[(23.8±5.7)%对(47.6±7.8)%].提示TRAIL可减轻糖尿病大鼠动脉粥样硬化病变. Four-week-old male Sprague-Dawley rats were rendered diabetic by intraperitoneal injection of streptozotocin (STZ) after feeding high-fat-diet for 8 weeks,and divided into diabetes group and tumor necrosis factorrelated apoptosis ligand(TRAIL) group.Normal rats severed as a control group.Treatment with TRAIL lasted for 3 months.Total cholesterol,triglycerides,low-density lipoprotein-cholesterol,blood glucose,and insulin levels were decreased in TRAIL group,as compared with diabetes group.Area of atherosclerotic lesion in TRAIL group [(23.8 ± 5.7) %] was significantly smaller than that in diabetes group [(47.6 ± 7.8) %].It suggested that TRAIL may reduce the area of atherosclerotic lesion in diabetic rats.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2014年第6期519-522,共4页 Chinese Journal of Endocrinology and Metabolism
基金 湖北省自然科学基金重点项目(2011CDA002) 武汉市学科带头人计划(201271130459)
关键词 肿瘤坏死因子相关的凋亡诱导配体 糖尿病 实验性 动脉粥样硬化 Tumor necrosis factor-related apoptosis ligand Diabetic mellitus, experimental Atherosclerosis
  • 相关文献

参考文献15

  • 1Baker SJ, Reddy EP. Transducers of life and death: TNF receptor super-family and associated proteins [ J 1. Oncogene, 1996,12 : 1-9.
  • 2Walczak H, MiUer RE, Ariail K, et al. Tumoricidal activity of tumornecrosis factor-related apoptosis-inducing ligand in vivo[ J]. Nat Med, 1999,5 : 157-163.
  • 3Zauli G, Pandolfl A, Gonelli A, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells [ J] Circ Res, 2003,92:732-740.
  • 4Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways [ J ]. Circulation, 2003,107 : 2250-2256.
  • 5Schoppet M, Sattler AM, Schaefer JR, et al. Osteoprotegelin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis[ J]. Atherosclerosis, 2006,184:446-447.
  • 6Michowitz Y, Goldstein E, Roth A, et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atheroscl- erosis[ J]. J Am Coll Cardiol, 2005,45 : 1018-1024.
  • 7Watt V, Chamberlain J, Steiner T, et al. TRAIL attenuates the development of atheroselerosis in apolipoprotein E deficient mice [ J]. Atherosclerosis, 2011,215:348-354.
  • 8Secehiero P, Candido R, Corallini F, et ah Systemic tumor necrosis factor-related apoptosis-indueing ligand delivery shows antiatherosele- rotic activity in apolipoprotein E-null diabetic mice [ J ]. Circulation 2006,114 : 1522-1530.
  • 9Di Bartolo BA, Chan J, Bennett MR, et al. TNF-related apoptosis- inducing ligand (TRAIL) protects against diabetes and atheroselerosis in ApoE-/- mice[ J]. Diabetologia, 201 1,54:3157-3167.
  • 10Zaali G, Toffoli B, di Iasio MG, et al. Treatment with recombinant tumor necrosis factor-related apoptosis-indueing ligand alleviates the severity of streptozotoein-indueed diabetes[ J]. Diabetes, 2010,59: 1261-1265.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部